
‘SuperAgers' are blessed with a different brain, according to 25 years of research
Carol Siegler, who lives in the Chicago suburb of Palatine, is a SuperAger. At 82, she won the American Crossword Puzzle Tournament for her age group, which she said she entered 'as a gag.'
'I've auditioned twice for 'Jeopardy!' and did well enough on it to be invited to the live auditions. Then Covid hit,' Siegler told me in 2022, when she was 85.
Today, Siegler is still going strong, well on her way to her 90th birthday, said Tamar Gefen, an associate professor of psychiatry and behavioral sciences at the Mesulam Institute for Cognitive Neurology and Alzheimer's Disease at Northwestern University in Chicago.
Gefen conducts research at Northwestern's SuperAging Program, which is currently studying 113 SuperAgers. Over the past 25 years, however, 80 SuperAgers have donated their brain tissue to the program, which has led to some fascinating discoveries.
CNN spoke to Gefen about those decades of work. She is a coauthor of a new analysis of the research that was published Thursday in Alzheimer's & Dementia, the journal of the Alzheimer's Association.
This interview has been lightly edited and condensed for clarity.
CNN: How do you define a SuperAger, and what have you found out about their behavior over the years?
Tamar Gefen: To be a SuperAger in our program at Northwestern, a person must be over 80 and undergo extensive cognitive testing. Acceptance in the study only occurs if the person's episodic memory — the ability to recall everyday events and past personal history — is as good or better than cognitively normal people in their 50s and 60s.
We have screened close to 2,000 individuals who think they may be a SuperAger and less than 10% meet the criteria. Over the past 25 years, we have studied about 300 SuperAgers — a number of whom have donated their brain for research.
One key trait of SuperAgers is that they seem to be highly social people. They value connection and are often active in their communities. This is interesting because we know isolation is a risk factor for developing dementia, and so staying socially active is a known protective feature.
Another common thread in all SuperAgers is a sense of autonomy, freedom and independence. They're making decisions and living their lives the way that they want to live.
I feel very strongly that successful aging is not just about sociability. If a person feels trapped, tethered or burdened, especially in a vulnerable state like poor health or older age, I think it can encroach on their entire psychosocial being.
But as far as healthy behaviors, SuperAgers run the gamut. We have SuperAgers with heart disease, diabetes, who aren't physically active, who don't eat any better than their similar age peers.
There is one SuperAger who drinks four beers every night. He laughs and says, 'Maybe it's done me wrong, but I'll never know.' He doesn't have an identical twin to compare his behavior to, so would he have lived to 108 instead of 98? We don't know.
CNN: Many of your most intriguing discoveries have come from studying donor brain tissue. What have you discovered about the memory center of the SuperAger brain?
Gefen: Our studies have shown that an area of the brain that is responsible for attention, motivation, and cognitive engagement — known as the cingulate cortex — is thicker in SuperAgers, even compared with those of people in their 50s and 60s.
In the hippocampus, the memory center of the brain, we found SuperAgers have three times fewer tau tangles when compared to their 'normal' peers. Abnormal formations of tau proteins are one of the key signs of Alzheimer's.
In Alzheimer's disease, tau also targets the neurons of the primary neurons of the cholinergic system — which is responsible for sustaining our attention in daily life. But that doesn't happen in the brain of a SuperAger. Therefore, the cholinergic system appears to be stronger, and likely more plastic and flexible for reasons that we're not sure about.
That's interesting, because I see SuperAgers as focused. They can pay close attention, engage and actively listen. How else could they recall 13 out of 15 random words after 30 minutes? I picture them engraving the words on their cortex with a chisel.
SuperAger brains also have bigger, healthier cells in the entorhinal cortex, an area essential for memory and learning, that has direct connections to the hippocampus. The entorhinal cortex, by the way, is one of the first areas of the brain to get hit by Alzheimer's disease.
In another study we examined every layer of cells within the entorhinal cortex of SuperAgers, and we painstakingly measured the size of the neurons. We found that in layer two, which is the layer that is most important for information transmission, SuperAgers had humongous, plump, intact, beautiful, gigantic entorhinal cortex neurons.
It was an incredible finding, because their entorhinal neurons were even larger than those in individuals who are much younger, some even in their 30s. That told us there is a structural integrity component at play — like the architecture, the bones, the skeleton of the neuron itself is sturdier.
We're expanding the studies of these neurons to understand their biochemical signatures, determine what makes them special, and see if these signatures are found in other types of neurons in the brain of SuperAgers. Are these same neurons particularly vulnerable in those with Alzheimer's disease, and if so, how and why?
CNN: What have you learned from your research about how the brain of a SuperAger reacts to injury, disease and stress?
Gefen: We're looking at the inflammatory system in the brain of SuperAgers, with the goal of understanding how the immune cells in their brain respond to disease and adapt to stress. Inflammation, once it crosses a certain threshold, is a major component of cell loss in Alzheimer's disease and nearly all other neurodegenerative diseases.
Compared with the brain of same-age peers, SuperAgers have fewer activated microglia, the resident immune cells of the brain, in their white matter. White matter is the brain's super highway, transporting information from one part of the brain to another.
Here's how it works: Microglia are activated because there is some kind of antigen or disease, typically something destructive in the brain. In some cases, however, microglia and other immune cells become hyperactive and go into overdrive, thus causing inflammation and possible damage.
The brain of a SuperAger, however, has fewer activated microglia. In fact, the levels of microglia were on par with people in their 30s, 40s and 50s. That could mean there is less junk or disease in the brain of a SuperAger so the microglia have no need to be active. Or it could mean microglia are responding efficiently to in clearing out disease or toxins, and because they are more plastic and adaptable, the microglia are able to activate, respond and then calm down.
All of this is fascinating — it may be that at the cellular level, the immune system of a SuperAger brain could be stronger or more adaptive, much like the layers of cells we found in the entorhinal cortex.
CNN: Whether or not you were born with the right genes to protect your brain sounds like the luck of the draw. What does that mean for the future?
Gefen: Genetics are tricky. It's not just whether you have a gene or not, it about how your internal and external environment works together to influence how a gene is 'turned on,' or expressed — some may be more highly expressed, some will have lower expression. This is the epigenetic part of the puzzle.
There is a list of candidate genes that we are starting to study very carefully, these are genes that also have a role in aspects of longevity, senescence, cell repair and cognitive reserve to name a few.
I'm excited about that, not only for the genetics that are heritable from parents, but also genetics at the cell level, that enable each neuron or immune cell to carry out its respective job within the brain. With the technology that's advancing so rapidly, I'm certain we're going to get to a point where prevention or modification at the genetic level will be part of the playbook.
Clearly, there is not a one target resolution for Alzheimer's disease. I know we all want that one easy fix but it's just simply not going to happen.
It's going to take many teams and many specialists to come together and create a kind of personalized cocktail for prevention or treatment. I think it's possible, but it's going to take time.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Electrophysiology Market worth US$21.72 billion by 2030 with 11.6% CAGR
DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The global Electrophysiology Market, valued at US$11.41 billion in 2024, stood at US$12.55 billion in 2025 and is projected to advance at a resilient CAGR of 11.6% from 2025 to 2030, culminating in a forecasted valuation of US$21.72 billion by the end of the period. The rise of the electrophysiology market can be attributed to several drivers: the increasing prevalence of cardiovascular diseases, including arrhythmias and atrial fibrillation; patients and healthcare providers are increasingly favoring minimally invasive procedures over traditional surgical interventions; electrophysiological techniques, such as catheter ablation, offer less invasive options for treating certain cardiac arrhythmias; and government support and initiatives aimed at improving healthcare infrastructure and funding research and development in electrophysiology also contribute to market growth. Download PDF Brochure: Browse in-depth TOC on "Electrophysiology Market" 322 - Tables62 - Figures330 - Pages By product, in 2024, electrophysiology ablation catheters are expected to be the leading segment in the medical device market. This anticipated growth is largely driven by the rising global prevalence of atrial fibrillation (AF) and various cardiac arrhythmias, which has increased the demand for minimally invasive ablation techniques. Recent technological advancements in catheter design, such as the introduction of contact force-sensing mechanisms, irrigated-tip designs, and high-power short-duration (HPSD) ablation systems, have greatly enhanced procedural safety, precision, and clinical outcomes. These innovations are contributing to wider acceptance and increased utilization of these catheters within the medical community. By indication, the electrophysiology market, divided by medical indications, includes segments such as atrial fibrillation, atrial flutter, and atrioventricular nodal reentry tachycardia. Atrial flutter, characterized by rapid heartbeats from the atria, is increasingly common, especially among the elderly, due to age-related cardiac changes. This rising prevalence has created a demand for advanced diagnosis and treatment options tailored to atrial flutter. Innovations in catheter ablation, advanced imaging techniques, and new pharmacological therapies reflect the urgency for effective arrhythmia management in an aging population. By geography, in 2024, North America, primarily the US and Canada, is set for significant growth in the medical technology market. The region is a global leader in medical innovations, especially in electrophysiology, often adopting breakthroughs ahead of others. With some of the highest healthcare spending globally, the US influences the uptake of advanced medical technologies, enhancing patient outcomes and operational efficiency. Strong A investment in research and development fosters innovation and creates a robust marketplace for new products and services, solidifying North America's role as a key driver of growth in the medical technology sector. Request Sample Pages : As of 2024, prominent players in the electrophysiology market are Johnson & Johnson Services, Inc. (US), Abbott (US), Medtronic (Ireland), Koninklijke Philips N.V. (Netherlands), GE Healthcare (US), Boston Scientific Corporation (US), Japan Lifeline Co., Ltd (Japan), Stereotaxis, Inc. (US), MicroPort Scientific Corporation (China), and BIOTRONIK (Germany). Abbott (US): Abbott Laboratories is a comprehensive healthcare company that operates across diverse sectors, including pharmaceuticals, medical devices, diagnostics, and nutrition. The company has established a significant presence in electrophysiology, particularly in the development of advanced medical devices for cardiac electrophysiology procedures. Abbott's portfolio in this specialized market includes sophisticated mapping systems, electrophysiology catheters, and related technologies designed for the precise diagnosis and management of cardiac arrhythmias. Furthermore, Abbott is likely engaged in ongoing research and development initiatives aimed at innovating and enhancing electrophysiological technologies to improve patient outcomes and procedural efficiencies. Koninklijke Philips N.V. (Netherlands) Koninklijke Philips N.V. Philips, a Netherlands-based multinational company, is a significant player in the healthcare sector, particularly within medical technology. The company develops an extensive range of products that enhance capabilities in cardiology, patient monitoring, diagnostic imaging, and electrophysiology. In the electrophysiology domain, Philips offers advanced solutions aimed at the identification and management of cardiac arrhythmias. This product suite includes high-precision imaging technologies, advanced mapping systems, and specialized electrophysiology catheters, all essential tools utilized by cardiology professionals. Key offerings include the EP WorkMate system, which serves as a comprehensive electrophysiology recording and reporting platform, facilitating efficient data capture and analysis during procedures. Additionally, Philips has introduced state-of-the-art X-ray imaging systems designed for enhanced visualization during electrophysiological interventions. The EP Navigator and EP-XT Mapping system are also part of their innovative portfolio, providing clinicians with advanced three-dimensional mapping capabilities that improve procedural accuracy and patient outcomes. For more information, Inquire Now! Related Reports: Defibrillator Market Cardiac Monitoring & Cardiac Rhythm Management Devices Market Ablation Technology Market Catheters Market Digital X-ray Market Get access to the latest updates on Electrophysiology Companies and Electrophysiology Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets
Yahoo
8 minutes ago
- Yahoo
UnitedHealth stock pops on Buffett's Berkshire share purchase
UnitedHealth Group's (UNH) stock jumped early Friday after Warren Buffett's Berkshire Hathaway (BRK-A, BRK-B) revealed Thursday it purchased 5 million shares last quarter. The insurance giant has suffered multiple setbacks in the past couple of years — with earnings misses piling on top of all that, the stock has been under constant pressure, and is down more than 45% year-to-date. But on the news of Berkshire's share purchase, the stock popped nearly 10% in early trading Friday. The last time Berkshire held a stake in the company was when Stephen Hemsley was CEO, between 2006 and 2017. Hemlsey has returned to the role after former CEO Andrew Witty stepped down in May — after a year of compounding headwinds. Last year, the company suffered one of the biggest cyberattacks in history on one of it's subsidiaries, Change Healthcare, which manages payments — creating havoc for health providers for months. The US Health and Human Services Department (HHS) had to step in and assist to help get payments flowing again. The company subsequently announced a larger-than-expected impact from the attack in mid-2024, dragging down major indices. At the end of the year, during the annual shareholder's meeting in New York City, insurance CEO Brian Thompson was shot to death. The struggles for the company didn't end there, as public backlash against the industry swelled in the aftermath, and the entire insurance industry was forced to address the issue of denied claims. In April this year, the company's stock crashed after an earnings miss shocked the Street. In May, Hemsley took over, and in the latest earnings call addressed the missteps the company has made, as well as the higher cost environment that it did not adjust in time to. "Beyond the environmental factors that are affecting the entire sector and more specifically to us, we have made pricing and operational mistakes as well as others," he said on the call. UnitedHealth's stock pop also helped boost the Dow (DJI), which was up about a half percent in early trading. Previously, UnitedHealth's losses dragged the Dow. In May, UnitedHealth was attributed with 88% of the Dow's decline year-to-date. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
Buffett Just Bought the Dip--Is This Health Giant the Comeback Play of the Year?
UnitedHealth Group (NYSE:UNH) just caught a lifelinestraight from two of Wall Street's most respected investors. Shares jumped 8.75% at 9.31am today, marking the stock's biggest intraday gain since 2020. The catalyst? Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway disclosed a fresh 5 million-share stake, while David Tepper (Trades, Portfolio)'s Appaloosa Management added another 2.3 million shares. That's a bold vote of confidence for a company that's been hammered this year, down 46% amid regulatory heat and earnings disappointments. Warning! GuruFocus has detected 5 Warning Sign with UNH. The health insurance heavyweight is navigating one of the roughest stretches in its history. A top executive was murdered late last year. In April, the company slashed its full-year outlook, then replaced its CEO with former chief Stephen Hemsley. Most recently, UnitedHealth issued a fresh profit forecast that came in below every single analyst estimatea stunning reversal for a business that had beaten expectations for over 60 straight quarters. So what broke the streak? UnitedHealth underestimated how quickly Americans would return to using medical servicesand set premiums too low as a result. Meanwhile, changes in government-subsidized coverage and payment models are eating into margins. If this trend holds, 2025 could mark the first annual adjusted EPS decline in nearly 20 years. Still, Buffett and Tepper stepping in suggests they see something others don't: a dominant business under temporary pressure, with long-term upside hiding in the wreckage. This article first appeared on GuruFocus.